ruxolitinib
Jakafi Approved To Treat Chronic GVHD in Adults and Children
The FDA approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure of one or two ...
OCTOBER 15, 2021
Oral JAK Inhibitor Shows Efficacy for Steroid-Refractory Graft-Versus-Host Disease
The oral JAK inhibitor ruxolitinib is associated with significant clinical improvement in patients with ...
JANUARY 29, 2021
Load more